Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR1313153

— · D

30b6f7ed-8ad2-5aba-bbe0-6c51d9b4b3b6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.570
  • INFLAMMATORY_RESPONSE+0.390
  • E2F_TARGETS+0.380
  • INTERFERON_GAMMA_RESPONSE+0.380
  • COMPLEMENT+0.340
  • IL6_JAK_STAT3_SIGNALING+0.330
  • PANCREAS_BETA_CELLS+0.300
  • INTERFERON_ALPHA_RESPONSE+0.280
  • KRAS_SIGNALING_UP+0.280
  • MYC_TARGETS_V1+0.250

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.470
  • WNT_BETA_CATENIN_SIGNALING-0.400
  • CHOLESTEROL_HOMEOSTASIS-0.380
  • ADIPOGENESIS-0.360
  • ESTROGEN_RESPONSE_LATE-0.350
  • NOTCH_SIGNALING-0.350
  • HEDGEHOG_SIGNALING-0.330
  • ANGIOGENESIS-0.320
  • FATTY_ACID_METABOLISM-0.310
  • GLYCOLYSIS-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-EW-A1OV-01A-11R-A144-07
breast-umap@18
—D0.846
2SRR8518292
breast-umap@18
—D0.833
3SRR2932829
head-neck@1
——0.806
4SRR8518185
breast-umap@18
—D0.804
5BSR_11_0107_E3_S77
breast-umap@18
—D0.799
6SRR8613734
breast-umap@18
—D0.792
7SRR8613787
breast-umap@18
—D0.790
8SRR8518222
breast-umap@18
—D0.789
9SRR8518291
breast-umap@18
—D0.789
10SRR1313142
breast-umap@18
—D0.789

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 20 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.570Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.390Idelalisib— uncovered
E2F_TARGETS0.380Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.380Idelalisib— uncovered
COMPLEMENT0.340Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.330Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
INTERFERON_ALPHA_RESPONSE0.280Inavolisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered
MYC_TARGETS_V10.250Inavolisib— uncovered
SPERMATOGENESIS0.240Inavolisib— uncovered
G2M_CHECKPOINT0.230Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
IL2_STAT5_SIGNALING0.160Idelalisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
COAGULATION0.070Binimetinib— uncovered
KRAS_SIGNALING_DN0.050Remibrutinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.020Remibrutinib— uncovered
APOPTOSIS0.010Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.010Inavolisib— uncovered